Topics

Biogen pays up to $710mm for Pfizer's CK1 inhibitor for CNS conditions

14:40 EST 15 Jan 2020 | Elsevier Business Intelligence

Biogen Inc. is acquiring Pfizer Inc.’s casein kinase 1 (CK1) inhibitor PF05251749 for patients with behavioral and neurolog...

Original Article: Biogen pays up to $710mm for Pfizer's CK1 inhibitor for CNS conditions

NEXT ARTICLE

More From BioPortfolio on "Biogen pays up to $710mm for Pfizer's CK1 inhibitor for CNS conditions"

Quick Search

Relevant Topic

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...